Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company established in 2017. The company is dedicated to advancing superior treatments for brain disease, operating within the Health and Wellness, Medical Devices, and Pharmaceutical industries. In October 2021, Chase Therapeutics secured a significant $20.00M Series B investment from Brain Trust Accelerator Fund and China Link Capital.
CHASE THERAPEUTICS
An innovative specialty pharmaceutical company advancing superior treatments for brain disease.
Founded 2017
2 employees
Series B
Total: $25.30M
Health and Wellness, Medical Devices +1
General Information
Company Name
CHASE THERAPEUTICS
Founded Year
2017
Employees
2
Industries
Health and Wellness, Medical Devices, Pharmaceutical
Funding Stage
Series B
Social
BounceWatch is an independent company data service, not affiliated with CHASE THERAPEUTICS. To contact CHASE THERAPEUTICS, visit chasetherapeutics.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does CHASE THERAPEUTICS compare?
A PDF of CHASE THERAPEUTICS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting CHASE THERAPEUTICS soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is CHASE THERAPEUTICS on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
Health and Wellness
About CHASE THERAPEUTICS
Business keywords: specialty pharmaceuticals, brain disease, treatment development, early-stage, product-based, neurology, pharmaceutical company, medical innovation
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series B | $20.00M | 2 |
|
20 Oct 2021 |
| Venture Round | Undisclosed | 2 |
|
29 Oct 2019 |
| Series A | $4.00M | - |
|
28 Aug 2018 |
| Series A | $1.30M | - |
|
21 Nov 2017 |
CHASE THERAPEUTICS Alternatives & Competitors
View All Alternatives
CHASE THERAPEUTICS vs
Cerebral Therapeutics, Inc.
United States
A clinical stage pharmaceutical company developing innovative treatments for neurological disease.
Series C
22 employees
Biotechnology, Health Care
CHASE THERAPEUTICS vs
IXALTIS SA
France
DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS
Venture round
2 employees
Biopharma, Biotechnology
CHASE THERAPEUTICS vs
Baudax Bio
United States
Advancing Acute Care Therapeutics
Post-IPO Equity
12 employees
Biotechnology, Health and Wellness
FAQ About CHASE THERAPEUTICS
An innovative specialty pharmaceutical company advancing superior treatments for brain disease.
CHASE THERAPEUTICS was founded in 2017.
CHASE THERAPEUTICS operates in Health and Wellness, Medical Devices and Pharmaceutical. Its work centres on specialty pharmaceuticals, brain disease, treatment development and early-stage.
CHASE THERAPEUTICS has approximately 2 employees.
CHASE THERAPEUTICS has completed 4 funding rounds, raising a total of $25.30M. The latest funding stage is Series B.
Top alternatives and competitors to CHASE THERAPEUTICS include Cerebral Therapeutics, Inc., IXALTIS SA, Baudax Bio, Carthera, Allodynic Therapeutics, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CHASE THERAPEUTICS and Cerebral Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for CHASE THERAPEUTICS, https://bouncewatch.com/company/chase-therapeutics, updated 14 January 2025. When citing, please name BounceWatch and link this page.
